Cross-reactive CD8+ T cell responses to tumor-associated antigens (TAAs) and homologous microbiota-derived antigens (MoAs)

We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and...

Full description

Saved in:
Bibliographic Details
Published inJournal of experimental & clinical cancer research Vol. 43; no. 1; pp. 87 - 14
Main Authors Cavalluzzo, Beatrice, Viuff, Marie Christine, Tvingsholm, Siri Amanda, Ragone, Concetta, Manolio, Carmen, Mauriello, Angela, Buonaguro, Franco M., Tornesello, Maria Lina, Izzo, Francesco, Morabito, Alessandro, Hadrup, Sine Reker, Tagliamonte, Maria, Buonaguro, Luigi
Format Journal Article
LanguageEnglish
Published England BioMed Central Ltd 20.03.2024
BioMed Central
BMC
Subjects
Online AccessGet full text

Cover

Loading…
Abstract We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP). A library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers. Homologous peptides were selected from the Cancer Antigenic Peptide Database, as well as Bacteroidetes/Firmicutes-derived peptides. They were incubated with CD8 + T cells from the peripheral blood of HLA-A*02:01 healthy individuals (n = 10) and cancer patients (n = 16). T cell recognition was identified using tetramer-staining analysis. Cytotoxicity assay was performed using as target cells TAP-deficient T2 cells loaded with MoA or the paired TuA. A total of 66 unique pMHC recognized by CD8+ T cells across all groups were identified. Of these, 21 epitopes from microbiota were identified as novel immunological targets. Reactivity against selected TAAs was observed for both HS and CP. pMHC tetramer staining confirmed CD8+ T cell populations cross-reacting with CTA SSX2 and paired microbiota epitopes. Moreover, PBMCs activated with the MoA where shown to release IFNγ as well as to exert cytotoxic activity against cells presenting the paired TuA. Several predicted microbiota-derived MoAs are recognized by T cells in HS and CP. Reactivity against TAAs was observed also in HS, primed by the homologous bacterial antigens. CD8+ T cells cross-reacting with MAGE-A1 and paired microbiota epitopes were identified in three subjects. Therefore, the microbiota can elicit an extensive repertoire of natural memory T cells to TAAs, possibly able to control tumor growth ("natural anti-cancer vaccination"). In addition, non-self MoAs can be included in preventive/therapeutic off-the-shelf cancer vaccines with more potent anti-tumor efficacy than those based on TAAs.
AbstractList BackgroundWe have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP).MethodA library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers. Homologous peptides were selected from the Cancer Antigenic Peptide Database, as well as Bacteroidetes/Firmicutes-derived peptides. They were incubated with CD8 + T cells from the peripheral blood of HLA-A*02:01 healthy individuals (n = 10) and cancer patients (n = 16). T cell recognition was identified using tetramer-staining analysis. Cytotoxicity assay was performed using as target cells TAP-deficient T2 cells loaded with MoA or the paired TuA.ResultsA total of 66 unique pMHC recognized by CD8+ T cells across all groups were identified. Of these, 21 epitopes from microbiota were identified as novel immunological targets. Reactivity against selected TAAs was observed for both HS and CP. pMHC tetramer staining confirmed CD8+ T cell populations cross-reacting with CTA SSX2 and paired microbiota epitopes. Moreover, PBMCs activated with the MoA where shown to release IFNγ as well as to exert cytotoxic activity against cells presenting the paired TuA.ConclusionsSeveral predicted microbiota-derived MoAs are recognized by T cells in HS and CP. Reactivity against TAAs was observed also in HS, primed by the homologous bacterial antigens. CD8+ T cells cross-reacting with MAGE-A1 and paired microbiota epitopes were identified in three subjects. Therefore, the microbiota can elicit an extensive repertoire of natural memory T cells to TAAs, possibly able to control tumor growth (“natural anti-cancer vaccination”). In addition, non-self MoAs can be included in preventive/therapeutic off-the-shelf cancer vaccines with more potent anti-tumor efficacy than those based on TAAs.
Background We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP). Method A library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers. Homologous peptides were selected from the Cancer Antigenic Peptide Database, as well as Bacteroidetes/Firmicutes-derived peptides. They were incubated with CD8 + T cells from the peripheral blood of HLA-A*02:01 healthy individuals (n = 10) and cancer patients (n = 16). T cell recognition was identified using tetramer-staining analysis. Cytotoxicity assay was performed using as target cells TAP-deficient T2 cells loaded with MoA or the paired TuA. Results A total of 66 unique pMHC recognized by CD8+ T cells across all groups were identified. Of these, 21 epitopes from microbiota were identified as novel immunological targets. Reactivity against selected TAAs was observed for both HS and CP. pMHC tetramer staining confirmed CD8+ T cell populations cross-reacting with CTA SSX2 and paired microbiota epitopes. Moreover, PBMCs activated with the MoA where shown to release IFN[gamma] as well as to exert cytotoxic activity against cells presenting the paired TuA. Conclusions Several predicted microbiota-derived MoAs are recognized by T cells in HS and CP. Reactivity against TAAs was observed also in HS, primed by the homologous bacterial antigens. CD8+ T cells cross-reacting with MAGE-A1 and paired microbiota epitopes were identified in three subjects. Therefore, the microbiota can elicit an extensive repertoire of natural memory T cells to TAAs, possibly able to control tumor growth ("natural anti-cancer vaccination"). In addition, non-self MoAs can be included in preventive/therapeutic off-the-shelf cancer vaccines with more potent anti-tumor efficacy than those based on TAAs.
We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP). A library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers. Homologous peptides were selected from the Cancer Antigenic Peptide Database, as well as Bacteroidetes/Firmicutes-derived peptides. They were incubated with CD8 + T cells from the peripheral blood of HLA-A*02:01 healthy individuals (n = 10) and cancer patients (n = 16). T cell recognition was identified using tetramer-staining analysis. Cytotoxicity assay was performed using as target cells TAP-deficient T2 cells loaded with MoA or the paired TuA. A total of 66 unique pMHC recognized by CD8+ T cells across all groups were identified. Of these, 21 epitopes from microbiota were identified as novel immunological targets. Reactivity against selected TAAs was observed for both HS and CP. pMHC tetramer staining confirmed CD8+ T cell populations cross-reacting with CTA SSX2 and paired microbiota epitopes. Moreover, PBMCs activated with the MoA where shown to release IFNγ as well as to exert cytotoxic activity against cells presenting the paired TuA. Several predicted microbiota-derived MoAs are recognized by T cells in HS and CP. Reactivity against TAAs was observed also in HS, primed by the homologous bacterial antigens. CD8+ T cells cross-reacting with MAGE-A1 and paired microbiota epitopes were identified in three subjects. Therefore, the microbiota can elicit an extensive repertoire of natural memory T cells to TAAs, possibly able to control tumor growth ("natural anti-cancer vaccination"). In addition, non-self MoAs can be included in preventive/therapeutic off-the-shelf cancer vaccines with more potent anti-tumor efficacy than those based on TAAs.
We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP).BACKGROUNDWe have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP).A library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers. Homologous peptides were selected from the Cancer Antigenic Peptide Database, as well as Bacteroidetes/Firmicutes-derived peptides. They were incubated with CD8 + T cells from the peripheral blood of HLA-A*02:01 healthy individuals (n = 10) and cancer patients (n = 16). T cell recognition was identified using tetramer-staining analysis. Cytotoxicity assay was performed using as target cells TAP-deficient T2 cells loaded with MoA or the paired TuA.METHODA library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers. Homologous peptides were selected from the Cancer Antigenic Peptide Database, as well as Bacteroidetes/Firmicutes-derived peptides. They were incubated with CD8 + T cells from the peripheral blood of HLA-A*02:01 healthy individuals (n = 10) and cancer patients (n = 16). T cell recognition was identified using tetramer-staining analysis. Cytotoxicity assay was performed using as target cells TAP-deficient T2 cells loaded with MoA or the paired TuA.A total of 66 unique pMHC recognized by CD8+ T cells across all groups were identified. Of these, 21 epitopes from microbiota were identified as novel immunological targets. Reactivity against selected TAAs was observed for both HS and CP. pMHC tetramer staining confirmed CD8+ T cell populations cross-reacting with CTA SSX2 and paired microbiota epitopes. Moreover, PBMCs activated with the MoA where shown to release IFNγ as well as to exert cytotoxic activity against cells presenting the paired TuA.RESULTSA total of 66 unique pMHC recognized by CD8+ T cells across all groups were identified. Of these, 21 epitopes from microbiota were identified as novel immunological targets. Reactivity against selected TAAs was observed for both HS and CP. pMHC tetramer staining confirmed CD8+ T cell populations cross-reacting with CTA SSX2 and paired microbiota epitopes. Moreover, PBMCs activated with the MoA where shown to release IFNγ as well as to exert cytotoxic activity against cells presenting the paired TuA.Several predicted microbiota-derived MoAs are recognized by T cells in HS and CP. Reactivity against TAAs was observed also in HS, primed by the homologous bacterial antigens. CD8+ T cells cross-reacting with MAGE-A1 and paired microbiota epitopes were identified in three subjects. Therefore, the microbiota can elicit an extensive repertoire of natural memory T cells to TAAs, possibly able to control tumor growth ("natural anti-cancer vaccination"). In addition, non-self MoAs can be included in preventive/therapeutic off-the-shelf cancer vaccines with more potent anti-tumor efficacy than those based on TAAs.CONCLUSIONSSeveral predicted microbiota-derived MoAs are recognized by T cells in HS and CP. Reactivity against TAAs was observed also in HS, primed by the homologous bacterial antigens. CD8+ T cells cross-reacting with MAGE-A1 and paired microbiota epitopes were identified in three subjects. Therefore, the microbiota can elicit an extensive repertoire of natural memory T cells to TAAs, possibly able to control tumor growth ("natural anti-cancer vaccination"). In addition, non-self MoAs can be included in preventive/therapeutic off-the-shelf cancer vaccines with more potent anti-tumor efficacy than those based on TAAs.
Abstract Background We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs). The present study aimed to assess the breadth of T-cell recognition specific to MoAs and the corresponding TAAs in healthy subjects (HS) and patients with cancer (CP). Method A library of > 100 peptide-MHC (pMHC) combinations was used to generate DNA-barcode labelled multimers. Homologous peptides were selected from the Cancer Antigenic Peptide Database, as well as Bacteroidetes/Firmicutes-derived peptides. They were incubated with CD8 + T cells from the peripheral blood of HLA-A*02:01 healthy individuals (n = 10) and cancer patients (n = 16). T cell recognition was identified using tetramer-staining analysis. Cytotoxicity assay was performed using as target cells TAP-deficient T2 cells loaded with MoA or the paired TuA. Results A total of 66 unique pMHC recognized by CD8+ T cells across all groups were identified. Of these, 21 epitopes from microbiota were identified as novel immunological targets. Reactivity against selected TAAs was observed for both HS and CP. pMHC tetramer staining confirmed CD8+ T cell populations cross-reacting with CTA SSX2 and paired microbiota epitopes. Moreover, PBMCs activated with the MoA where shown to release IFNγ as well as to exert cytotoxic activity against cells presenting the paired TuA. Conclusions Several predicted microbiota-derived MoAs are recognized by T cells in HS and CP. Reactivity against TAAs was observed also in HS, primed by the homologous bacterial antigens. CD8+ T cells cross-reacting with MAGE-A1 and paired microbiota epitopes were identified in three subjects. Therefore, the microbiota can elicit an extensive repertoire of natural memory T cells to TAAs, possibly able to control tumor growth (“natural anti-cancer vaccination”). In addition, non-self MoAs can be included in preventive/therapeutic off-the-shelf cancer vaccines with more potent anti-tumor efficacy than those based on TAAs.
ArticleNumber 87
Audience Academic
Author Ragone, Concetta
Hadrup, Sine Reker
Izzo, Francesco
Tvingsholm, Siri Amanda
Tornesello, Maria Lina
Cavalluzzo, Beatrice
Tagliamonte, Maria
Manolio, Carmen
Mauriello, Angela
Morabito, Alessandro
Buonaguro, Luigi
Viuff, Marie Christine
Buonaguro, Franco M.
Author_xml – sequence: 1
  givenname: Beatrice
  surname: Cavalluzzo
  fullname: Cavalluzzo, Beatrice
– sequence: 2
  givenname: Marie Christine
  surname: Viuff
  fullname: Viuff, Marie Christine
– sequence: 3
  givenname: Siri Amanda
  surname: Tvingsholm
  fullname: Tvingsholm, Siri Amanda
– sequence: 4
  givenname: Concetta
  surname: Ragone
  fullname: Ragone, Concetta
– sequence: 5
  givenname: Carmen
  surname: Manolio
  fullname: Manolio, Carmen
– sequence: 6
  givenname: Angela
  surname: Mauriello
  fullname: Mauriello, Angela
– sequence: 7
  givenname: Franco M.
  surname: Buonaguro
  fullname: Buonaguro, Franco M.
– sequence: 8
  givenname: Maria Lina
  surname: Tornesello
  fullname: Tornesello, Maria Lina
– sequence: 9
  givenname: Francesco
  surname: Izzo
  fullname: Izzo, Francesco
– sequence: 10
  givenname: Alessandro
  surname: Morabito
  fullname: Morabito, Alessandro
– sequence: 11
  givenname: Sine Reker
  surname: Hadrup
  fullname: Hadrup, Sine Reker
– sequence: 12
  givenname: Maria
  surname: Tagliamonte
  fullname: Tagliamonte, Maria
– sequence: 13
  givenname: Luigi
  orcidid: 0000-0002-6380-7114
  surname: Buonaguro
  fullname: Buonaguro, Luigi
BackLink https://www.ncbi.nlm.nih.gov/pubmed/38509571$$D View this record in MEDLINE/PubMed
BookMark eNp9kktv1DAUhSNURB_wB1igSEioCAXsPPxYVaPhVamIzbC2bpybjEdJPNhOJebX4zQtmnbBynFyzqd7T855cjLaEZPkNSUfKRXsk6cFKVlG8jIjBSFldniWnFFesUxKxk6Onk-Tc-93hDAqqXyRnBaiIrLi9Cw5rJ31PnMIOphbTNefxYd0k2rs-9Sh39vRo0-DTcM0WJeB91YbCNikMAbT4ejTy81q5d_He5Nu7WB729nJp4PRztbGBsgadBF97Phho-Nl8ryF3uOr-_Mi-fX1y2b9Pbv5-e16vbrJdJWLkGkKgtOKCKwa0tbIOICgglCQJZZ1yysEJuscmxhBzKLmTJNWShQUo6coLpLrhdtY2Km9MwO4P8qCUXcvrOsUuGB0jyovcl2TFjXWoqRAoAbR8FI3rIkoyCPramHtp3rARuMYHPSPoI-_jGarOnuraMy7oCWNhMt7grO_J_RBDcbPccOIMTeVS15QQhmdpW-fSHd2cmPMShWk4IKXlMmoereoOogbbBH6sPW2n4KJ_06tuGCy5JKTKHxzPPu_oR_KEAViEei5Ew5bpU2AmRNXMX3cQc29U0vvVMxa3fVOHaI1f2J9oP_H9BdV9Nsj
CitedBy_id crossref_primary_10_4103_bbrj_bbrj_271_24
crossref_primary_10_1007_s11427_024_2831_x
crossref_primary_10_1177_17588359251324882
crossref_primary_10_1136_jitc_2024_010192
crossref_primary_10_3390_biomedicines12112429
Cites_doi 10.1038/nprot.2012.037
10.1002/(sici)1097-0215(19980703)77:1<19::aid-ijc4>3.0.co;2-2
10.1016/s0169-5002(03)00244-7
10.3390/cancers11010038
10.1016/s0952-7915(96)80019-7
10.1016/j.cell.2009.09.033
10.1016/s0167-5699(98)01299-7
10.1126/science.aan3706
10.1186/s12967-018-1662-9
10.1084/jem.20020242
10.3389/fimmu.2021.769799
10.1097/00000658-199608000-00011
10.1186/s12967-022-03512-6
10.1084/jem.20160526
10.1016/j.csbj.2021.12.035
10.1038/nbt.3662
10.1038/ni.f.219
10.3390/microorganisms7010014
10.1073/pnas.0909122107
10.1038/ni.2640
10.1084/jem.190.5.705
10.1084/jem.184.2.647
10.1158/1078-0432.CCR-07-1909
10.3390/cancers14010140
10.1126/science.abc4552
10.1038/nature09944
10.1016/j.chom.2012.08.004
10.1016/j.ctrv.2018.04.009
10.1136/gutjnl-2019-319654
10.1038/s41579-020-0433-9
10.1016/j.ymthe.2020.12.005
10.1172/JCI32205
10.1016/j.ceb.2015.08.002
10.1016/j.mib.2013.03.009
10.1016/j.immuni.2015.01.010
10.1002/ijc.2910630313
10.1042/BCJ20160510
10.1111/imm.13037
10.1186/s12943-023-01776-0
10.1186/s12885-021-08720-9
10.1038/nmeth.1345
10.4049/jimmunol.174.3.1709
10.1186/s12967-022-03681-4
10.1038/nri.2017.7
10.1016/j.mam.2023.101192
ContentType Journal Article
Copyright 2024. The Author(s).
COPYRIGHT 2024 BioMed Central Ltd.
2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
The Author(s) 2024
Copyright_xml – notice: 2024. The Author(s).
– notice: COPYRIGHT 2024 BioMed Central Ltd.
– notice: 2024. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: The Author(s) 2024
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
3V.
7X7
7XB
88E
8FI
8FJ
8FK
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
M1P
PHGZM
PHGZT
PIMPY
PJZUB
PKEHL
PPXIY
PQEST
PQQKQ
PQUKI
7X8
5PM
DOA
DOI 10.1186/s13046-024-03004-z
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Central (Corporate)
Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
Medical Database (Alumni Edition)
ProQuest Hospital Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni)
Medical Database
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database
ProQuest Health & Medical Research Collection
ProQuest One Academic Middle East (New)
ProQuest One Health & Nursing
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Open Access Full Text
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
Publicly Available Content Database
ProQuest One Academic Middle East (New)
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest One Health & Nursing
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest Medical Library
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
Health & Medical Research Collection
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Medical Library (Alumni)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Publicly Available Content Database

MEDLINE
MEDLINE - Academic

Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 4
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 1756-9966
EndPage 14
ExternalDocumentID oai_doaj_org_article_232cb0feceb841a0aba8d74cd6d8e5a2
PMC10953141
A786947970
38509571
10_1186_s13046_024_03004_z
Genre Journal Article
GeographicLocations United States--US
GeographicLocations_xml – name: United States--US
GrantInformation_xml – fundername: Regione Campania
  grantid: POR FESR 2014/2020 "Campania OncoTerapie"
– fundername: Ministero della Salute
  grantid: "Ricerca Corrente" Project L2/3
– fundername: Ministero della Salute
  grantid: "Ricerca Corrente" Project L2/13
GroupedDBID ---
0R~
29K
2WC
4.4
5GY
5VS
7X7
88E
8FI
8FJ
AAFWJ
AAJSJ
AASML
AAYXX
ABDBF
ABUWG
ACGFO
ACGFS
ADBBV
ADRAZ
ADUKV
AENEX
AFKRA
AFPKN
AHBYD
AHMBA
AHYZX
ALIPV
ALMA_UNASSIGNED_HOLDINGS
AMKLP
AOIJS
BAWUL
BCNDV
BENPR
BFQNJ
BMC
BPHCQ
BVXVI
C6C
CCPQU
CITATION
CS3
D-I
DIK
DU5
E3Z
EBD
EBLON
EBS
ESX
F5P
FYUFA
GROUPED_DOAJ
HMCUK
HYE
IAO
IEA
IHR
IHW
INH
INR
ITC
KQ8
M1P
M48
M~E
O5R
O5S
OK1
OVT
P2P
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
PSQYO
RBZ
RNS
ROL
RPM
RSV
SMD
SOJ
TR2
TUS
UKHRP
~8M
-5E
-5G
-A0
-BR
3V.
ACRMQ
ADINQ
C24
CGR
CUY
CVF
ECM
EIF
NPM
7XB
8FK
AZQEC
DWQXO
K9.
PJZUB
PKEHL
PPXIY
PQEST
PQUKI
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c528t-c1a871508e5d0fbe67aa81801a94e4bf75ea69b2ed004024b76c0f99e81e8e533
IEDL.DBID M48
ISSN 1756-9966
0392-9078
IngestDate Wed Aug 27 01:19:44 EDT 2025
Thu Aug 21 18:34:43 EDT 2025
Fri Jul 11 16:13:40 EDT 2025
Sat Jul 26 00:18:52 EDT 2025
Thu May 22 21:26:04 EDT 2025
Wed Feb 19 02:11:13 EST 2025
Tue Jul 01 02:26:52 EDT 2025
Thu Apr 24 22:55:38 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 1
Language English
License 2024. The Author(s).
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c528t-c1a871508e5d0fbe67aa81801a94e4bf75ea69b2ed004024b76c0f99e81e8e533
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0002-6380-7114
OpenAccessLink https://doaj.org/article/232cb0feceb841a0aba8d74cd6d8e5a2
PMID 38509571
PQID 3037874169
PQPubID 105475
PageCount 14
ParticipantIDs doaj_primary_oai_doaj_org_article_232cb0feceb841a0aba8d74cd6d8e5a2
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10953141
proquest_miscellaneous_2973101611
proquest_journals_3037874169
gale_healthsolutions_A786947970
pubmed_primary_38509571
crossref_citationtrail_10_1186_s13046_024_03004_z
crossref_primary_10_1186_s13046_024_03004_z
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2024-03-20
PublicationDateYYYYMMDD 2024-03-20
PublicationDate_xml – month: 03
  year: 2024
  text: 2024-03-20
  day: 20
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
– name: London
PublicationTitle Journal of experimental & clinical cancer research
PublicationTitleAlternate J Exp Clin Cancer Res
PublicationYear 2024
Publisher BioMed Central Ltd
BioMed Central
BMC
Publisher_xml – name: BioMed Central Ltd
– name: BioMed Central
– name: BMC
References JL Round (3004_CR12) 2010; 107
TS Ghosh (3004_CR39) 2020; 69
B Cavalluzzo (3004_CR32) 2021; 14
C Ragone (3004_CR25) 2022; 20
E Rinninella (3004_CR3) 2019; 7
O Türeci (3004_CR37) 1998; 77
M Tagliamonte (3004_CR33) 2021; 12
E Schooten (3004_CR36) 2018; 67
M Otte (3004_CR43) 2001; 61
II Ivanov (3004_CR14) 2009; 139
Y Fan (3004_CR6) 2021; 19
V Dutoit (3004_CR23) 2002; 196
G Bricard (3004_CR45) 2005; 174
B Routy (3004_CR8) 2018; 359
C Zang (3004_CR44) 2021; 21
Y Shen (3004_CR13) 2012; 12
DJ Loftus (3004_CR21) 1996; 184
RS Andersen (3004_CR29) 2012; 7
JR Brestoff (3004_CR5) 2013; 14
C Manolio (3004_CR31) 2022; 20
M Tagliamonte (3004_CR34) 2023; 22
CM Paulos (3004_CR10) 2007; 117
D Mason (3004_CR19) 1998; 19
A Khosravi (3004_CR4) 2013; 16
M Arumugam (3004_CR2) 2011; 473
SR Hadrup (3004_CR28) 2009; 6
S Piquer-Esteban (3004_CR38) 2021; 20
E Thursby (3004_CR1) 2017; 474
L Buonaguro (3004_CR26) 2021; 29
MG von Herrath (3004_CR16) 1996; 8
GD Sepich-Poore (3004_CR7) 2021; 371
A Petrizzo (3004_CR30) 2018; 16
M Levy (3004_CR17) 2017; 17
F Brasseur (3004_CR41) 1995; 63
C Gur (3004_CR11) 2015; 42
JL Weon (3004_CR46) 2015; 37
N Tai (3004_CR18) 2016; 213
ML Sprouse (3004_CR15) 2019; 156
L Vujanovic (3004_CR24) 2007; 13
AK Bentzen (3004_CR27) 2016; 34
M Mori (3004_CR40) 1996; 224
MJ Pittet (3004_CR22) 1999; 190
K Tajima (3004_CR42) 2003; 42
S Vivarelli (3004_CR9) 2019; 11
KC Garcia (3004_CR20) 2009; 10
L Buonaguro (3004_CR35) 2023; 92
References_xml – volume: 7
  start-page: 891
  issue: 5
  year: 2012
  ident: 3004_CR29
  publication-title: Nat Protoc
  doi: 10.1038/nprot.2012.037
– volume: 77
  start-page: 19
  issue: 1
  year: 1998
  ident: 3004_CR37
  publication-title: Int J Cancer
  doi: 10.1002/(sici)1097-0215(19980703)77:1<19::aid-ijc4>3.0.co;2-2
– volume: 42
  start-page: 23
  issue: 1
  year: 2003
  ident: 3004_CR42
  publication-title: Lung Cancer
  doi: 10.1016/s0169-5002(03)00244-7
– volume: 11
  start-page: 38
  issue: 1
  year: 2019
  ident: 3004_CR9
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers11010038
– volume: 8
  start-page: 878
  issue: 6
  year: 1996
  ident: 3004_CR16
  publication-title: Curr Opin Immunol
  doi: 10.1016/s0952-7915(96)80019-7
– volume: 139
  start-page: 485
  issue: 3
  year: 2009
  ident: 3004_CR14
  publication-title: Cell
  doi: 10.1016/j.cell.2009.09.033
– volume: 19
  start-page: 395
  issue: 9
  year: 1998
  ident: 3004_CR19
  publication-title: Immunol Today
  doi: 10.1016/s0167-5699(98)01299-7
– volume: 359
  start-page: 91
  issue: 6371
  year: 2018
  ident: 3004_CR8
  publication-title: Science
  doi: 10.1126/science.aan3706
– volume: 16
  start-page: 286
  issue: 1
  year: 2018
  ident: 3004_CR30
  publication-title: J Transl Med
  doi: 10.1186/s12967-018-1662-9
– volume: 196
  start-page: 207
  issue: 2
  year: 2002
  ident: 3004_CR23
  publication-title: J Exp Med
  doi: 10.1084/jem.20020242
– volume: 12
  start-page: 769799
  year: 2021
  ident: 3004_CR33
  publication-title: Front Immunol
  doi: 10.3389/fimmu.2021.769799
– volume: 224
  start-page: 183
  issue: 2
  year: 1996
  ident: 3004_CR40
  publication-title: Ann Surg
  doi: 10.1097/00000658-199608000-00011
– volume: 20
  start-page: 316
  issue: 1
  year: 2022
  ident: 3004_CR25
  publication-title: J Transl Med
  doi: 10.1186/s12967-022-03512-6
– volume: 213
  start-page: 2129
  issue: 10
  year: 2016
  ident: 3004_CR18
  publication-title: J Exp Med
  doi: 10.1084/jem.20160526
– volume: 61
  start-page: 6682
  issue: 18
  year: 2001
  ident: 3004_CR43
  publication-title: Cancer Res
– volume: 20
  start-page: 421
  year: 2021
  ident: 3004_CR38
  publication-title: Comput Struct Biotechnol J
  doi: 10.1016/j.csbj.2021.12.035
– volume: 34
  start-page: 1037
  issue: 10
  year: 2016
  ident: 3004_CR27
  publication-title: Nat Biotechnol
  doi: 10.1038/nbt.3662
– volume: 10
  start-page: 143
  issue: 2
  year: 2009
  ident: 3004_CR20
  publication-title: Nat Immunol
  doi: 10.1038/ni.f.219
– volume: 7
  start-page: 14
  issue: 1
  year: 2019
  ident: 3004_CR3
  publication-title: Microorganisms
  doi: 10.3390/microorganisms7010014
– volume: 107
  start-page: 12204
  issue: 27
  year: 2010
  ident: 3004_CR12
  publication-title: Proc Natl Acad Sci U S A
  doi: 10.1073/pnas.0909122107
– volume: 14
  start-page: 676
  issue: 7
  year: 2013
  ident: 3004_CR5
  publication-title: Nat Immunol
  doi: 10.1038/ni.2640
– volume: 190
  start-page: 705
  issue: 5
  year: 1999
  ident: 3004_CR22
  publication-title: J Exp Med
  doi: 10.1084/jem.190.5.705
– volume: 184
  start-page: 647
  issue: 2
  year: 1996
  ident: 3004_CR21
  publication-title: J Exp Med
  doi: 10.1084/jem.184.2.647
– volume: 13
  start-page: 6796
  issue: 22 Pt 1
  year: 2007
  ident: 3004_CR24
  publication-title: Clin Cancer Res
  doi: 10.1158/1078-0432.CCR-07-1909
– volume: 14
  start-page: 140
  issue: 1
  year: 2021
  ident: 3004_CR32
  publication-title: Cancers (Basel)
  doi: 10.3390/cancers14010140
– volume: 371
  start-page: eabc4552
  issue: 6536
  year: 2021
  ident: 3004_CR7
  publication-title: Science
  doi: 10.1126/science.abc4552
– volume: 473
  start-page: 174
  issue: 7346
  year: 2011
  ident: 3004_CR2
  publication-title: Nature
  doi: 10.1038/nature09944
– volume: 12
  start-page: 509
  issue: 4
  year: 2012
  ident: 3004_CR13
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2012.08.004
– volume: 67
  start-page: 54
  year: 2018
  ident: 3004_CR36
  publication-title: Cancer Treat Rev
  doi: 10.1016/j.ctrv.2018.04.009
– volume: 69
  start-page: 1218
  issue: 7
  year: 2020
  ident: 3004_CR39
  publication-title: Gut
  doi: 10.1136/gutjnl-2019-319654
– volume: 19
  start-page: 55
  issue: 1
  year: 2021
  ident: 3004_CR6
  publication-title: Nat Rev Microbiol
  doi: 10.1038/s41579-020-0433-9
– volume: 29
  start-page: 10
  issue: 1
  year: 2021
  ident: 3004_CR26
  publication-title: Mol Ther
  doi: 10.1016/j.ymthe.2020.12.005
– volume: 117
  start-page: 2197
  issue: 8
  year: 2007
  ident: 3004_CR10
  publication-title: J Clin Invest
  doi: 10.1172/JCI32205
– volume: 37
  start-page: 1
  year: 2015
  ident: 3004_CR46
  publication-title: Curr Opin Cell Biol
  doi: 10.1016/j.ceb.2015.08.002
– volume: 16
  start-page: 221
  issue: 2
  year: 2013
  ident: 3004_CR4
  publication-title: Curr Opin Microbiol
  doi: 10.1016/j.mib.2013.03.009
– volume: 42
  start-page: 344
  issue: 2
  year: 2015
  ident: 3004_CR11
  publication-title: Immunity
  doi: 10.1016/j.immuni.2015.01.010
– volume: 63
  start-page: 375
  issue: 3
  year: 1995
  ident: 3004_CR41
  publication-title: Int J Cancer
  doi: 10.1002/ijc.2910630313
– volume: 474
  start-page: 1823
  issue: 11
  year: 2017
  ident: 3004_CR1
  publication-title: Biochem J
  doi: 10.1042/BCJ20160510
– volume: 156
  start-page: 305
  issue: 4
  year: 2019
  ident: 3004_CR15
  publication-title: Immunology
  doi: 10.1111/imm.13037
– volume: 22
  start-page: 75
  issue: 1
  year: 2023
  ident: 3004_CR34
  publication-title: Mol Cancer
  doi: 10.1186/s12943-023-01776-0
– volume: 21
  start-page: 1007
  issue: 1
  year: 2021
  ident: 3004_CR44
  publication-title: BMC Cancer
  doi: 10.1186/s12885-021-08720-9
– volume: 6
  start-page: 520
  issue: 7
  year: 2009
  ident: 3004_CR28
  publication-title: Nat Methods
  doi: 10.1038/nmeth.1345
– volume: 174
  start-page: 1709
  issue: 3
  year: 2005
  ident: 3004_CR45
  publication-title: J Immunol
  doi: 10.4049/jimmunol.174.3.1709
– volume: 20
  start-page: 472
  issue: 1
  year: 2022
  ident: 3004_CR31
  publication-title: J Transl Med
  doi: 10.1186/s12967-022-03681-4
– volume: 17
  start-page: 219
  issue: 4
  year: 2017
  ident: 3004_CR17
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri.2017.7
– volume: 92
  start-page: 101192
  year: 2023
  ident: 3004_CR35
  publication-title: Mol Aspects Med
  doi: 10.1016/j.mam.2023.101192
SSID ssj0061919
Score 2.401632
Snippet We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from microorganisms (MoAs)....
Background We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from...
BackgroundWe have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from...
Abstract Background We have recently shown extensive sequence and conformational homology between tumor-associated antigens (TAAs) and antigens derived from...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 87
SubjectTerms Analysis
Antigenic determinants
Antigens
Antigens, Neoplasm
Bar codes
Binomial distribution
Cancer
CD8-Positive T-Lymphocytes
Epitopes, T-Lymphocyte
Ethylenediaminetetraacetic acid
Histocompatibility antigens
HLA histocompatibility antigens
Humans
Immune system
Lymphocytes
Microbiota
Microbiota (Symbiotic organisms)
Neoplasms
Peptides
Peptides - chemistry
Software
T cells
Tumors
SummonAdditionalLinks – databaseName: DOAJ Open Access Full Text
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3Ni9QwFA-yB_Eirp_VVSN4UJawTT_S9DiOLoswnmZhbyFfZRecVqYdD_PX73tJp0wR9OKxTUObvK_fa5LfI-SjwQpIprFMSGNZoTPwg0aUkKp4L6XRAEkwUVz9EFfXxfeb8uao1BfuCYv0wHHiLiDiW5M23nojC65TbbR0VWGdcNKXOnhfiHmHZCr6YMgKeH04IiPFRc9xAZBBPGIpUkyx_SwMBbb-P33yUVCab5g8ikCXT8jjETrSRfzkU_LAt0_Jw9W4OP6M7Jf4KgYoMPgwuvwqz-ma4q95uo1bYX1Ph44Ou023ZXoUjHcUZhdJOXv6ab1Y9J_h2tHbboN-sdv1dHMX2ZoGzRwo7O9Zj1UHPZ6T68tv6-UVG0srMFtmcmCWa8iUAJz50qWN8aLSGk99c10XvjBNVXotapN5h1aeFaYSNm3q2kvuoU-evyAnbdf6V4SKvLGYJLnM6iIsXNa5xqzQ5RakVCeEH2Za2ZF3HMtf_FQh_5BCRekoeI0K0lH7hJxPfX5F1o2_Pv0FBTg9iYzZ4QbokRr1SP1LjxLyHsWv4vHTye7VopKiLqq6ShNydtAMNRp6rwABgMsDVAvj_DA1g4micHXrQUoqlAdDaM0T8jIq0vStuQTEVlbQImcqNhvMvKW9uw004BypAnnBX_-P4b8hj7JoHuA3z8jJsN35twC3BvMuWNY9O8AopA
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Health & Medical Collection
  dbid: 7X7
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1Jb9QwFLagSIgLYidQwEgcQJXVLI7jnNAwUFVIw2kqzc3yFlqJmZRJhsP8et5zPKERUo-JY8XJ277n5XuEfDBYAck0lglpLOM6Bz9oRAmpivdSGg2QBBPFxQ9xfsG_r8pVnHDr4rbKg08Mjtq1FufIT8HVgm4BfKg_X_9mWDUKV1djCY275B5Sl-GWrmo1JlyQG4TCHhAhBUNcfzg0I8Vpl-GSIIMIxVIknWL7SWAK_P3_e-kbYWq6hfJGTDp7RB5GMElng_Qfkzt-84TcX8Tl8qdkP8dXMcCFwavR-Vd5QpcUJ-vpdtgc6zvat7Tfrdst01FU3lH430jT2dGPy9ms-wTXjl62a_SU7a6j66uBv6nXzIEK_5n0WLTQ4xm5OPu2nJ-zWGyB2TKXPbOZhtwJ4JovXdoYLyqt8Rx4pmvuuWmq0mtRm9w7tPucm0rYtKlrLzMPfYriOTnatBv_klBRNBbTJpdbzcNSZl1ozBNdYa0TdUKyw59WNjKRY0GMXypkJFKoQToKXqOCdNQ-ISdjn-uBh-PWp7-gAMcnkUM73Gi3P1U0SQVY0pq08dYbyTOdaqOlqziM0MEH6Twh71D8ajiQOnoCNaukqHlVV2lCjg-aoaLpd-qfoibk_dgMRovC1RsPUlKhYBiC7SwhLwZFGsdaSMBwZQUtcqJik4-ZtmyuLgMxeIbkgRnPXt0-rtfkQT4oPvjIY3LUb3f-DUCr3rwN9vMXEU4gTA
  priority: 102
  providerName: ProQuest
Title Cross-reactive CD8+ T cell responses to tumor-associated antigens (TAAs) and homologous microbiota-derived antigens (MoAs)
URI https://www.ncbi.nlm.nih.gov/pubmed/38509571
https://www.proquest.com/docview/3037874169
https://www.proquest.com/docview/2973101611
https://pubmed.ncbi.nlm.nih.gov/PMC10953141
https://doaj.org/article/232cb0feceb841a0aba8d74cd6d8e5a2
Volume 43
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV1bb9MwFLZ2kaa9IO4ERjESD6ApECeO7Twg1JZNE1InNLXSxItlOw6btDbQpAjGn-fYuWgRg5dKbXKa2Of2nTj-DkKvtOuApAsTMqFNSFUMcVCzFEoVa4XQCiCJKxRnp-xkQT-dp-dbqGt31E5gdWtp5_pJLdZXb39-__UBHP69d3jB3lXELe-FkG3CyBFIhdfbaBcyE3eOOqP9qgLUCiTrNs7cKreP9hIBKTTlZJCnPJ3_30H7RtYavlF5I0Ud30V3WmyJx40x3ENbdnUf7c3a1fMH6PfUXSoEmOiDHJ5-FPgQz7F7eI_XzcuytsJ1ievNslyHqlWdzTHMv6PtrPDr-XhcvYHvOb4oly5ylpsKLy8bPqdahTmY9I-BxKwEiYdocXw0n56EbfOF0KSxqENDFNRSAN9smkeFtowr5faFE5VRS3XBU6tYpmObuzgQU82ZiYoss4JYkEmSR2hnVa7sE4RZUhhXRuWxUdQvbWaJcnVjnhiTsyxApJtqaVpmctcg40r6CkUw2WhKwmWk15S8DtBhL_Ot4eX479kTp8H-TMep7X8o119l66ISsKXRUWGN1YISFSmtRM4p3GEOA1JxgF44_ctmg2ofGeSYC5ZRnvEoQAedacjOkiVgBAiKgHthnC_7w-DETrlqZUFL0jcQc-CbBOhxY0n9vXYGGSAxsLHBYIZHVpcXniicODJBQsnTf_7pM7QfN_YP4fIA7dTrjX0OKKvWI7TNz_kI7U6OTj-fjfyzipF3J_g8m3z5A33uJjc
linkProvider Scholars Portal
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF5VqQRcEG8MhS4SSKBqVdux1-sDQmnaKqVNhFAq9bbdl2klEpfYAZEfxW9kxo9QC6m3HpP1xuvMzDfzeXZnCHmrsQOSzgzjQhsWqRBwUPMYqIpzQmgFIQkSxfGEj06jz2fx2Qb5056FwW2VLSZWQG1zg-_IdwFqQbcgfEg_Xf1g2DUKs6ttC41aLY7d719A2YqPR_sg33dheHgwHY5Y01WAmTgUJTOBApIAcYmLrZ9pxxOl8MBzoNLIRTpLYqd4qkNnUcHDSCfc-FmaOhE4mIMvQAHyN6M-UJke2dw7mHz52mI_sJGqlQj4ZM6QSbTHdATfLQJMQjL4ReZjmSu26rjCqmPA_37hmmPsbtq85gUPH5D7TfhKB7W-PSQbbv6I3Bk3CfrHZDXEWzGIRCscpcN9sUOnFNMDdFFvx3UFLXNaLmf5gqlGOZylIGEsDFrQ99PBoPgAny29yGeIzfmyoLPLumJUqZgFo_nZmTHOYcYTcnorgnhKevN87p4TyvuZQaJmQ6OiKnma9hUyU9s3xvLUI0H7T0vT1D7HFhzfZcWBBJe1dCTcRlbSkSuP7KznXNWVP268eg8FuL4Sq3ZXX-SLb7IBAQnRq9F-5ozTIgqUr7QSNolghRYeSIUe2Ubxy_oI7Bp75CARPI2SNPE9stVqhmzAppD_TMMjb9bDABMoXDV3ICVZtSjD8D7wyLNakdZr7QuIGuMERkRHxToP0x2ZX15UpcgDLFcYRMGLm9e1Te6OpuMTeXI0OX5J7oW1EQBCb5FeuVi6VxDYlfp1Y02UnN-2Af8Fe0deWw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Cross-reactive+CD8+%2B+T+cell+responses+to+tumor-associated+antigens+%28TAAs%29+and+homologous+microbiota-derived+antigens+%28MoAs%29&rft.jtitle=Journal+of+experimental+%26+clinical+cancer+research&rft.au=Cavalluzzo%2C+Beatrice&rft.au=Viuff%2C+Marie+Christine&rft.au=Tvingsholm%2C+Siri+Amanda&rft.au=Ragone%2C+Concetta&rft.date=2024-03-20&rft.eissn=1756-9966&rft.volume=43&rft.issue=1&rft.spage=87&rft_id=info:doi/10.1186%2Fs13046-024-03004-z&rft_id=info%3Apmid%2F38509571&rft.externalDocID=38509571
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1756-9966&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1756-9966&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1756-9966&client=summon